
    
      This study is designed to be pilot, single-center, open-label, single-arm, prospective, phase
      II trial of patient with NSCLC with pleurla effusion. Approximately 40 patients will be
      enrolled into the trial, and study will be performed to 31Dec2018 from IRB and Korea: MFDS
      approval date.

      Docetaxel will be administed to interpleural space using medical pleuroscopy in malignant
      effusion with lung cancer. Response evaluation will be done until confiramtion of disease
      progression.
    
  